Vivo Capital Closes Its Public Fund with Commitments of Over $740 Million
PALO ALTO, Calif., May 07, 2025--(BUSINESS WIRE)--Vivo Capital ("Vivo" or "the Firm"), a leading global investment firm focused exclusively on healthcare and life sciences, has closed the third cycle of its Vivo Opportunity Fund and its affiliates (the "Public Fund") with over $740 million in commitments. The Public Fund invests in preclinical and clinical stage life sciences businesses that are developing or commercializing novel therapies for unmet medical needs.
Vivo Opportunity Fund is an evergreen fund with three-year investment cycles. The third cycle of Vivo Opportunity Fund will follow the same strategy as its first and second cycles, leveraging Vivo's deep scientific and technical capabilities to invest in small- and mid-cap biotechnology and life sciences companies. The aim of these investments is to capture value from breakthroughs and clinical milestones.
The first two cycles of Vivo Opportunity Fund have successfully invested in companies that went on to announce significant milestones, such as regulatory approvals, or that were subsequently acquired by global pharmaceutical companies. Recent examples include Verona Pharmaceuticals and its Ohtuvayre™ treatment for chronic obstructive pulmonary disease (approved by the FDA in 2024), Geron Corporation's drug RYTELO™ for low-risk myelodysplastic syndrome (approved by the FDA in 2024), Avadel Pharmaceuticals and its Lumryz™ for narcolepsy (approved by the FDA in 2023) and, most recently, Soleno Therapeutics, which announced in March 2025 that its VYKAT™ XR treatment for Prader-Willi Syndrome has been approved for use by the FDA. This represents the first approved drug to treat the hallmark symptoms of this disease. Vivo-backed companies that were acquired by major pharmaceutical businesses include Sierra Oncology (acquired by GSK for $1.9 billion in 2022), Gracell Therapeutics (acquired by AstraZeneca for $1.2 billion in 2023), RayzeBio, Inc. (acquired by Bristol-Myers Squibb for $4.1 billion in 2024), Chinook Therapeutics (acquired by Novartis for $3.2 billion in 2023) and Kadmon (acquired by Sanofi for $1.9 billion in 2021).
Kevin Dai, Managing Director at Vivo Capital, said: "As with its predecessors, the third cycle of the Vivo Opportunity Fund brings a venture capital mindset to the public markets, combining our long-term capital with our deep industry knowledge and experience to capture value for our investors. This strategy supports our approach of looking for the best opportunities across the entire healthcare spectrum."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Salmonella recall of 20 million eggs from Walmart, Safeway, Ralphs, among others
Another salmonella outbreak caused the recall of 1.7 million dozen eggs — meaning roughly more than 20 million less eggs to fry — and has sickened people in seven states. The aforementioned eggs were distributed to Walmart, Safeway, chains owned by Kroger and various other independent and chain supermarkets. Hilmar, California's August Egg Company, a division of Gemperle Enterprises, produced the eggs and issued the recall Friday. 'August Egg Company is not selling fresh shell eggs at this time,' the company-written, FDA-posted recall notice said. 'Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens.' READ MORE: Public health alert: Deadly E. coli found in beef sent to Whole Foods stores What eggs have been recalled? Packaging for the recalled eggs will have plant code P-6562 or CA5330 with the Julian Dates between 32 to 126. The eggs that went to Walmart stores had sell by dates from March 4 through June 19. Other retailers got eggs with 'sell by dates' from March 4 through June 4. August Egg says these eggs went to stores in California, Washington, Illinois, Nevada, Arizona, Wyoming, New Mexico, Nebraska, and Indiana. The recall section of Walmart's website says this also involves its stores in Alaska, Colorado, Hawaii, Iowa, Idaho, Kansas, Michigan, Montana, North Dakota, Ohio, Oklahoma, Oregon, Texas and Wisconsin. ▪ Marketside (a Walmart store brand): Organic Large Cage Free Brown Eggs in cartons of 12 and 18; Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ First Street (a Smart & Final house brand): Cage Free Large Brown loose eggs. ▪ Clover: Organic Large Brown Eggs, one dozen. ▪ Nulaid: One dozen Medium Brown Cage Free, one dozen Jumbo Brown Cage Free. ▪ O Organics: Cage Free Large Brown, six eggs; and Large Brown, 12 and 18 eggs. This brand will be found at Safeway and other Albertson's-owned stores. ▪ Raley's (store brand): Large Cage Free Brown, 12 eggs: Organic Large Cage Free Brown, 12 and 18 eggs. ▪ Simple Truth: Cage Free Large Brown and Medium Brown 18 eggs. This brand will be found at Food 4 Less, Ralphs and other Kroger-owned chains. ▪ Sun Harvest: Organic Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ Sunnyside: Organic Large Cage Free Brown Eggs in cartons of 12 and 18; and Large Cage Free Brown Eggs in cartons of 12 and 18. What's up with the salmonella outbreak? Saturday's outbreak update from the Centers for Disease Control and Prevention says 79 people have been sickened in this outbreak with 21 hospitalizations. Of those 79, 63 are in California. The remaining 16 break down as Nevada and Washington (four each); Arizona, three; Nebraska and New Jersey (two each); and Kentucky, one. Salmonella outbreaks tend to be very undercounted because most people recover without medical attention. What is salmonella? The CDC estimates about 1.35 million people in the United States will get salmonella each year. Of that number, 26,400 will be hospitalized, usually driven to the hospital by bloody diarrhea, and 420 will die. Usually, salmonella just means a few days of diarrhea, vomiting, fever and stomachaches. What you should do now If you have any of the recalled eggs listed above, return them to the store for a refund or throw them deep into the garbage. If you have any questions about the recalls, call August Farms at 800-710-2554, noon to 8 p.m., Eastern time.
Yahoo
4 hours ago
- Yahoo
These Popular Eggs Are Being Recalled Over Salmonella Risk
If you've been living for your morning sunny-side eggs…well, brace yourself. The August Egg Company—the parent behind Sunnyside, Clover, Raley's, and a few other brands—is recalling a whopping 1.7 million dozen eggs due to a potential salmonella outbreak. Yep, it's serious.. The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention have flagged the August Company's 'brown cage-free and brown certified organic egg' for possible contamination, meaning you might want to double-check that carton in your fridge before cracking it open. If you didn't know, Salmonella is that sneaky bacteria behind food poisoning and can cause anything from mild stomach upset to serious illness. These eggs were shipped to Walmart stores and other grocers in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. They have a best-by date from March 4 to June 19 and food codes P-6562 or CA5330. Not sure if your eggs are on the list? The FDA has a full rundown of all the recalled brands you can check out. And if the cartons in your fridge match any of the food codes or best-by-dates, toss them out immediately. While it's somewhat okay to eat an egg past its expiration date, this isn't the case. The FDA has already connected a current salmonella outbreak to the eggs. As of now, a total of 79 cases have been reported in seven states, while 21 people have been hospitalized. We get it: eggs are pricey, and tossing them feels like a waste. But don't risk it. Plus, most places will give you a full refund. And if your eggs touched any surfaces, wipe those down like your life depends on it. If after eating you feel dizzy, nauseous, or get a fever—don't play it cool. Call your doctor. This is serious business. Trust me, as a four-time survivor of food poisoning, you don't want to take any chances. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
Yahoo
6 hours ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
